X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!
















Authors
 

Abbott: What lies ahead?

(Aug 24, 2005)

With the advent of the product patent law in India, Indian arms of MNC pharma companies will be in the limelight, as they will look to launch patented products from their parents’ folio. Being an MNC pharma company, Abbott also stands to gain from the same. In this article, we take a look at the company’s past performance and what lies for it in the future.

Abbott: Other income fillip

(Oct 1, 2004)

Abbott India has declared its 3QFY05 results (November year ending). The net profit of the company has grown by 120 % in the August quarter, other income having provided a large chunk of this growth. The topline growth has however been marginal. Operating margins too have been disappointing and have declined by 310 basis point to 22% from 25% on a YoY basis. For the nine-month period however the picture has been encouraging as far as topline is concerned, with a growth of 9%. The operating margi

MNC pharma: The opportunity

(Sep 14, 2004)

There are many MNC pharma companies operating in India. While some of them have really entrenched themselves in the country, others are involved more in being a trading entity. Companies such as Aventis, Glaxo and Pfizer have full fledged operations in India, others like Abbott, Sanofi, Novartis are more or less trading companies. This is one of the major criteria that also determine the depth of these companies in the Indian market place. In this article, we review the MNC companies that are pr

Abbott India: Modest growth

(Oct 3, 2003)

MNC pharma major, Abbott India has recently announced its 3QFY04 results. While the company registered a modest 7% increase in topline, bottomline shot up by a significant 60%. For 9mFY04, Abbot registered a 5% growth in net sales and 29% rise in net profits. In this context, let us briefly evaluate the company’s performance.

Abbott India: DPCO blues

(Jul 22, 2003)

Following the worldwide sale of BASF AG’s (Knoll’s parent company) pharmaceutical business to Abbot Laboratories in Dec ’00, Knoll Pharma had become a subsidiary of BASF AG. Consequently, Knoll Pharma was renamed as Abbott India Ltd (AIL) with effect from July ’02. Abbot Laboratories is a global healthcare company devoted to discovery, development, manufacture and marketing of pharmaceuticals, nutritional and medical products including devices and diagnostics. The merger is expected to increase

Knoll Pharma:1QFY03 net up 53%

(Jul 2, 2002)

Knoll Pharmaceuticals, (now a subsidiary of Abott Labs) has registered marginal decline in sales for 1QFY03. However, a sharp rise in operating margins helped the company register a 53% rise in profits. Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market.

Knoll Pharma: Buyback on hold

(Jun 18, 2002)

Knoll Pharmaceuticals, (now a subsidiary of Abott Labs) has registered a marginal decline in sales for 1QFY03. However, a sharp rise in operating margins helped the company register a 53% rise in profits. Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market.

Knoll Pharma: Consolidating operations

(Mar 4, 2002)

Knoll Pharma has declared a 33% drop in net profits for the year ended November'01. The company has changed its accounting year from December to November year ending. Hence the latest results are not strictly comparable as this year of the company was for a period of 11 months.

Knoll Pharma: Mounting competition

(Dec 28, 2001)

Following the worldwide merger of Knoll AG and Abbott Inc, Knoll Pharma, is now a subsidiary of Abbott Inc. Though the company remains the leader in the domestic insulin business, it is facing severe heat of competition from domestic players. One would expect that the product basket of the company could receive a boost with new parent in place. However, unless this happens the company would face stiff domestic competition.

Knoll Pharma: 3QFY02 PBT rise 26%

(Oct 23, 2001)

Knoll Pharmaceuticals, subsidiary of Abbot AG, has declared its 3QFY02 report card. While sales have grown by around 3%, operating margins have jumped 240 basis points. Higher operating margins, coupled with interest savings helped to achieve a 26% growth in PBT. However, net profit dropped by 48% due to inclusion of an extraordinary income to the tune of Rs 132 m in the last year from sale of property at Sion, Mumbai. Similarly the first half also had an extra-ordinary income of Rs 161 m on ac

Knoll Pharma: An update

(Aug 29, 2001)

Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market with around 55% market share in the insulin business. However, most of the company's drugs are under DPCO coverage. The company’s financials went through a bumpy ride in the last six months due to two important price changes ordered by DPCO.

Knoll Pharma: PBT rises 29% in 1HFY02

(Jul 16, 2001)

Knoll Pharmaceuticals, formerly Indian subsidiary of Knoll AG, has declared excellent performance for first half of FY02 in line with our expectation (Insert Link to Knoll Pharma Article dated 30th April'01: Better days ahead). Apparently, net profit has dropped by 27% due to inclusion of an extraordinary income to the tune of Rs 161 m in the last year from sale of mutual fund units. The performance in second quarter is remarkable considering that there was a drop in operating profit in the firs

Knoll Pharma open offer: Pros and cons

(May 7, 2001)

Abbott Laboratories Inc has made an open offer to the shareholders of Knoll Pharma to acquire 20% of the company’s equity at Rs 328 per share. This follows Knoll Pharma’s parent company’s sell-out to Abbott Inc. Is it worth for Knoll Pharma shareholders to consider this option?

Knoll Pharma: Better days ahead

(Apr 30, 2001)

Knoll Pharmaceuticals, (formerly Indian subsidiary of Knoll AG) has declared a drop in net profit for 1QFY02 by 23%. Knoll Pharma is the leading player in the domestic insulin, anti-diabetic, pain control, antacid market. The drop in net profit was in line with our expectations following a cut in Ibuprofen prices by NPPA in January this year. Ibuprofen is a bulk drug which is used in pain management segment. As Knoll Pharma is a market leader in Ibuprofen market, the price cut had a severe impac

Knoll Pharma: Other income buoys net

(Feb 23, 2001)

Knoll Pharma has reported a 5% jump in the net profit on the back of a 14.3% jump in the turnover. Even last year the company derived a substantial portion of its revenues from other income. Thus on a like to like basis, the profit growth has been an impressive 55%, if one were to exclude the non–recurring other income in both the years after adjusting the tax paid on that.

Knoll Pharma: A strong dose

(Jul 29, 2000)

A 30% growth in earnings on a 13.6% growth in the topline is a strong enough dose but Knoll has during the quarter also sold units of mutual funds which have realised an extraordinary profit of Rs 160.5 m.

Knoll Pharma: The anti-diabetes king consolidates

(Jul 4, 2000)

Knoll Pharmaceuticals is the Indian subsidiary of Knoll AG, which in turn is part of the health and nutrition division of BASF AG. Knoll is a leading player in the Indian insulin, pain control and antacid market with brands such as Brufen (anti–rheumatic), Digene (antacid), Epilex (anti–epilepsy) and Cremmafin (laxative).


Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS